

**AWMSG ADVICE SUPERSEDED BY  
NICE GUIDANCE (TA449)  
NICE GUIDANCE ISSUED JUNE 2017**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

**Final Appraisal Recommendation  
Advice No: 2112 – July 2012**

**Everolimus (Afinitor<sup>®</sup>▼)**

**Submission by Novartis Pharmaceuticals UK Ltd**

**Recommendation of AWMSG**

**Everolimus (Afinitor<sup>®</sup>▼) is recommended as an option for use within NHS Wales for the treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.**

**Additional note:**

- AWMSG is of the opinion that everolimus (Afinitor<sup>®</sup>▼) is appropriate for specialist only prescribing within NHS Wales for the stated indication.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), lay/patient/carer perspective (where available) and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Novartis Pharmaceuticals UK Ltd
Date of first issue	July 2012
Last reviewed	August 2016



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2112:  
Everolimus (Afinitor<sup>®</sup>). July 2012.

